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SuMMARy – Medullary thyroid carcinoma (MTC) is a rare malignancy that originates from 
parafollicular (C cells) of the thyroid and accounts for 2-4% of all thyroid malignancies. MTC may be 
sporadic or inherited, the latter as part of the Men 2 syndromes. Germline mutations in the RET 
proto-oncogene (Rearranged during Transfection) are driver mutations in hereditary MTC, whereas 
somatic RET mutations and, less frequently, RAS mutations, have been described in tumor tissues of 
sporadic MTC. Genetic screening for germline mutations in RET proto-oncogene identifies gene 
carriers of germline mutations. That enables primary prevention (the avoidance of disease onset by 
total prophylactic thyroidectomy), or at least secondary prevention (early detection) of the disease. 
Radical surgery with complete tumor resection is still pivotal in attaining cure for MTC. despite re-
cent advances, the treatment of advanced, metastatic, and progressive MTC remains challenging. 
Metastatic MTC can have an indolent clinical course; therefore, it is necessary to assess which patient 
to cure and when to initiate the treatment. Multidisciplinary boards of various specialists involved in 
the diagnostics and therapy of the patients with MTC in highly specialized centers with a high vol-
ume of patients provide optimal patient management. Multikinase inhibitors (MKi) vandetanib and 
cabozantinib were approved for the treatment of progressive or symptomatic metastatic/unresectable 
MTC. Although these treatments have been shown to improve progression-free survival (pFS) with 
higher overall response rates (oRR) compared with placebo, no MKi has been shown to increase the 
overall survival (oS) yet, except in the subgroup of patients with RETM918T-mutations on cabozan-
tinib therapy. As these drugs are nonselective, significant off-target toxicities may occur. Recently, 
next-generation small-molecule tyrosine kinase inhibitors (TKis) have been developed. These highly 
selective ReT-inhibitors are specifically designed for highly potent and selective targeting of onco-
genic ReT alterations, making them promising drugs for the treatment of advanced MTC. The selec-
tive ReT-inhibitor selpercatinib has been very recently registered for the treatment of RET-mutated 
thyroid cancer. 
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Medullary thyroid carcinoma (MTC) is a rare type 
of thyroid malignancy and a member of the neuroen-
docrine type of tumors. MTC arises from parafollicu-
lar cells, or C cells, derived from the neural crest, which 
produce calcitonin, which serves as a specific MTC-
tumor marker, as well as some other peptides, includ-
ing carcinoembryonic antigen (CeA) which is used as 
a non-specific tumor marker in MTC.
MTC accounts for less than 5% (2-4%) of all thy-
roid cancers1. According to current SeeR (Surveil-
lance, epidemiology, and end Results) data, medul-
lary thyroid carcinoma accounts for 1-2% of thyroid 
cancers in the united States, which is much lower than 
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previously cited, primarily due to the significant in-
crease in the relative incidence of papillary thyroid car-
cinoma (pTC) over the last several decades2.
MTC mostly occurs in the fifth or sixth decade of 
life when sporadic, but earlier in the cases of hereditary 
disease. MTC is extremely rare in children, except for 
the hereditary forms, making the probability of a he-
reditary form very high. in contrast with thyroid epi-
thelial cell tumors, the female to male ratio is nearly 
equal.
Approximately 35% of patients with MTC with 
palpable thyroid nodules have cervical metastases. 
Roughly 10% (7-23%) have distant metastases at dis-
ease presentation3. however, distant metastases appear 
during follow-up in approximately 20-40% of patients 
with MTC. distant metastases are the leading cause 
of MTC-related death4. Recent data shows lower dis-
ease-specific mortality rates, probably due to earlier 
discovery of metastatic disease5. The reported 10-year 
MTC-related mortality rates vary from 13.4% to 
38.0%5.
The stage of the disease at diagnosis and the pos-
sibility of radical surgical resection are the most im-
portant factors in achieving cure in MTC. The classical 
main prognostic factors in MTC are age, tumor size, 
local and distant metastases, somatic M918T muta-
tions, calcitonin, and CeA doubling times6.
Etiology
inherited tumors are part of the Men2 syndromes, 
which are transmitted in families as autosomal domi-
nant traits due to activating germline point mutations 
of the RET proto-oncogene.
The predominant driver mutations in MTCs are 
RET (Rearranged during Transfection) and RAS pro-
to-oncogene mutations that are detected in approxi-
mately 90% of MTCs7. RET mutations can occur spo-
radically as somatic mutations in tumor tissue or can 
be inherited as germline mutations8. in the latter case, 
they are associated with hereditary MTCs.
patients with Men2A syndrome can have medul-
lary thyroid cancers, pheochromocytomas, and para-
thyroid hyperplasia or adenomas. previously consid-
ered a separate entity, FMTC (familial medullary thy-
roid cancer) is today considered a variant of Men2A 
syndrome. patients with Men2B have medullary thy-
roid carcinoma, mucosal neuromas, pheochromocyto-
mas which are usually bilateral and often malignant, 
occasionally cafe-au-lait spots, and possibly Gardner’s 
syndrome (mucocutaneous pigmented nevi and small 
intestinal polyps). Some of these features result in a 
distinct phenotype known as marphanoid.
Germline mutations of the RET proto-oncogene 
cause hereditary cancer, whereas somatic RET muta-
tions are frequently present in sporadic MTC tumor 
tissues. RET encodes a transmembrane receptor; 
point-activating RET mutations promote continuous 
phosphorylation of a distinct set of tyrosine residues, 
triggering intracellular signaling pathways responsible 
for cell survival, differentiation, and proliferation. RET 
is activated by point mutation in MTC, as opposed to 
pTCs (papillary thyroid cancer) where it is activated 
by chromosomal rearrangement.
in FMTC, germline mutations in specific func-
tional regions of RET are found in almost all patients. 
in Men 2A and FMTC, mutations are typically lo-
cated within the cysteine-rich region in the extracel-
lular domain. Almost 90% of Men 2A mutations are 
present in a single codon, codon 634. in contrast, in 
FMTC they are more evenly distributed along the 
cysteine-rich region. in Men 2B, the vast majority of 
germline mutations occur in the intracellular tyrosine 
kinase domain of RET, in codon 918.
in sporadic MTCs, somatic mutations of the RET 
gene in tumor tissue can be detected in approximately 
50% (20-80%) of patients. Almost all of those affect 
codon 918, although they have also been identified in 
a few other gene regions. Mutations in this codon 918 
are thought to be a predictor of a poor prognosis9.
Germline RET mutations, either de novo or in pre-
viously unrecognized families with hereditary MTCs, 
can be present in patients with apparently sporadic 
MTCs. Therefore, screening for germline RET muta-
tions and genetic counselling should be offered to all 
newly diagnosed patients with MTC.
if germline RET mutation in a patient with MTC 
is detected, screening for RET oncogene mutation in 
the blood is the first step in family members at risk10. 
neck ultrasound and calcitonin measurements are in-
dicated in mutation carriers to assess the possible pres-
ence of the disease. every mutation carrier with either 
a thyroid mass or elevated calcitonin levels should re-
ceive an immediate thyroidectomy. if no thyroid nod-
ule is detected and the serum calcitonin is normal ac-
cording to the reference range for the specific age 
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group, prophylactic thyroidectomy should be consid-
ered at the appropriate age, depending on the muta-
tion type found (usually according to the ATA-crite-
ria) in order to take out the thyroid gland before the 
disease is initiated11. The recommended age for total 
prophylactic thyroidectomy in carriers of germline 
RET mutations varies depending on the type of muta-
tion. The most aggressive germline M918T mutation 
requires total thyroidectomy as early as within the first 
year of life. Surgery can be postponed until age five in 
high-risk C634F and A883F mutations, unless there is 
an increase in calcitonin levels. Carriers of other muta-
tion types should be monitored from age five onwards 
by measuring calcitonin levels and performing neck 
uS, and prophylactic thyroidectomy may in some cases 
even be avoided or at least postponed to a more mature 
age; the decision should be made based on genetic 
counselling of the parents12.
in Men2A, the tumors follow a rather benign 
course somewhat similar to that of follicular cancer 
and can usually be controlled by surgery. Men2B tu-
mors are much more aggressive and often cause death 
in the second or third decade of life13.
MTCs caused by specific germline RET mutations 
have a very different median age of disease onset (but 
mostly occurring from early childhood to early adult-
hood, depending on the driver mutation), as well as 
different tumor aggressiveness. MTCs, as part of the 
Men 2B syndrome, are very aggressive malignancies. 
in contrast, hereditary MTCs as part of Men 2A syn-
drome (including FMTC) have a more indolent clini-
cal course compared with the sporadic MTCs14. how-
ever, if somatic ReT mutations, especially ReT 
M918T, are present in sporadic MTCs, their biologic 
behavior is more aggressive compared with the ones 
without it15. 
Clinical presentation
hereditary MTC is usually multicentric, bilateral, 
and associated with C-cell hyperplasia, while sporadic 
MTC is unicentric and unilateral.
Approximately 35% of patients with MTC with 
palpable thyroid nodules already have cervical metas-
tases. Roughly 10% (7-23%) have distant metastases at 
disease presentation3. however, distant metastases ap-
pear during follow-up in approximately 20-40% of pa-
tients with MTC and are the leading cause of MTC-
related death. The symptomatic clinical disease will 
occur in approximately 30-60% of patients with MTC 
with evidence of persistent disease after initial treat-
ment at different time intervals during the subsequent 
follow-up, depending on the persistent tumor volume 
and progression rate.
MTC biologic behavior varies widely; from indo-
lent in some cases, to rapidly progressive in others. Tu-
mor marker doubling times can rather reliably predict 
biologic behavior. Currently approved systemic thera-
pies for MTC still do not provide prolongation of 
overall survival. Therapy should be initiated in symp-
tomatic disease, lesions close to vital structures, high-
tumor burdens, and/or rapid (within one year) disease 
progression on imaging (as defined by ReCiST 1.1 
criteria)16, 17.
Advanced MTC is associated with the secretion of 
the variety of peptides (serotonin, histaminase, vasoac-
tive intestinal peptide, prostaglandins, kinins, etc.) 
causing clinical symptoms such as flushing or diarrhea 
that disrupt patient quality of life and needing man-
agement.
in inherited MTC, symptoms related to other en-
docrine neoplasia within Men2 syndromes can ap-
pear and should be treated accordingly. 
Diagnosis
in pathology, MTC is sometimes referred to as 
“the great mimic” because of its morphological hetero-
geneity and the ability to resemble virtually all other 
primary thyroid tumors. Therefore, calcitonin expres-
sion is mandatory for the pathohistological diagnosis 
of MTC.
Calcitonin and CeA serum levels have valuable di-
agnostic, prognostic, and predictive value as markers in 
MTC. Their serum concentrations directly correlate 
with the C-cell mass. preoperative calcitonin levels 
strongly correlate to tumor diameter, while postopera-
tive levels are a valuable indicator of the probable ex-
tent of the disease18. Calcitonin levels exceeding 500 
pg/ml are suggestive of distant metastatic disease, and 
patients should be submitted to additional imaging di-
agnostics. postoperative serum calcitonin should be 
measured 60-90 days after total thyroidectomy.
patients that are considered “biochemically cured” 
with postoperative basal calcitonin levels within the 
normal range have a 10-year survival rate of 97.7%. 
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however, biochemical recurrence occurs within 7.5 
years in about 3% of them.
Carcinoembryonic antigen (CeA) is a non-specific 
tumor marker for MTC. it is usually measured in gas-
trointestinal malignancies, and therefore MTC is 
sometimes discovered during follow-up of those pa-
tients as an incidental finding. however, the primary 
use of CeA in MTC is in monitoring for potential 
disease progression in already diagnosed and treated 
MTC.
doubling times of the postoperative basal levels of 
tumor markers calcitonin and CeA are defined as the 
time intervals in which the marker levels have doubled, 
and have been established as prognostic markers in 
MTC19. doubling times of tumor markers calcitonin 
and CeA accurately predict tumor behavior, recur-
rence rates, and cancer-related death. A calcitonin 
doubling time that exceeds six months is associated 
with a 5-year survival rate of 92% and 10-year survival 
rate of 37%. The prognosis in patients with MTC is 
much worse in patients with shorter doubling times: a 
5-year survival rate of 25% and 10-year survival rate of 
8%, respectively. however, in aggressive, progressive, 
and poorly differentiated MTCs, calcitonin values 
may actually decrease in time while the CeA levels 
and doubling time increases, the latter being often 
considered a more accurate predictor of rapidly pro-
gressive MTC. 
Serial tumor marker levels measurements provide 
useful information on the doubling times. Calcitonin 
doubling times should be based on at least four con-
secutive measurements in the same laboratory using 
the same assay, preferably over a 2-year time period. 
Clinically relevant disease is rarely detected if calcito-
nin levels are below 150 pg/ml. however, increase in 
calcitonin and CeA levels raises the likelihood of 
structural disease6.
except for the tumor markers, diagnostic proce-
dures used in the diagnosis, assessment of the thera-
peutic efficacy, and follow-up of MTC-patients may 
include, according to clinical findings: neck ultraso-
nography (uS) with fine-needle aspiration (FnA) and 
calcitonin levels measurements in FnA-washouts, and 
contrast-enhanced CT or MRi of the neck and chest 
with uS of the abdomen in suspicious findings20. 
workup for distant metastases is indicated in suspi-
cious clinical findings and/or serum calcitonin levels 
exceeding 500 pg/ml and may include CT and/or 
MRi of the chest and abdomen, bone scintigraphy, F-
dopA-peT/CT (if available, with high sensitivity 
and specificity for MTC, in contrast to FdG-peT/
CT)21. Although FdG-peT/CT is not recommended 
in the staging of the indolent MTCs due to generally 
low avidity for FdG, it can be useful for assessing ad-
vanced, especially dedifferentiated and rapidly pro-
gressive disease22.
Today, scintigraphy with 131-i-MiBG or tect-
rotide (octreotide) has less importance than in previ-
ous years. however, positive findings on 131-i-MiBG 
or expression of somatostatin receptors could prove as 
a therapeutic target in the absence of other, more ef-
fective therapeutic options or when they are exhausted. 
when the feasibility of radionuclide therapy is being 
explored, gallium-68 (68Ga) somatostatin analogue 
peT/CT, as the newer imaging procedure than oc-
treotide/tectrotide scintigraphy, can provide informa-
tion of the expression of somatostatin receptors.
Screening for pheochromocytoma and hyperpara-
thyroidism is necessary for the assessment and follow-
up of all patients with confirmed or suspected Men 
2A syndrome until germline mutations are excluded.
MTC treatment
Surgical management – Total thyroidectomy with 
central (region vi) lymph node neck dissection is the 
surgical standard of care and the only curative treat-
ment for MTC. Additionally, unilateral or bilateral 
cervical lymph node dissection is performed if needed, 
based on the imaging, serological (tumor markers), 
and/or intraoperative findings. patients with recurrent 
local/regional disease in the neck and mediastinum are 
candidates for repeat neck surgery with either curative 
or palliative intent, and some patients may also benefit 
from external beam radiation therapy (eBRT)5. Sur-
gery in patients with MTC should be performed by 
surgeons with substantial experience in this field, espe-
cially when lateral neck dissection is needed.
Radiotherapy – External beam radiotherapy 
(EBRT) is indicated in the presence of extensive local/
locoregional disease, residual tumor, and/or extranodal 
tumor extension23. however, there is no evidence of 
the oS benefit with the addition of adjuvant EBRT in 
completely resected disease, only better locoregional 
disease control in patients at high risk of cervical re-
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lapse. There is therefore no consensus on the indica-
tions for adjuvant eBRT.
Palliative radiotherapy has its role, especially in the 
presence of painful bone metastases and/or risk of 
pathologic fractures24. 
Systemic therapy
no effective curative therapeutic option exists for 
patients with locally/locoregionally advanced inoper-
able disease and/or distant metastases25. unfortunately, 
chemotherapy regimens have only limited response 
rates, and the data from clinical studies on efficacy are 
insufficient, given the retrospective design, small pa-
tient cohorts, and the of robust evaluation response 
criteria such as ReCiST. The most active drug has 
been doxorubicin, alone or in combination with cispla-
tin, which achieved the response rate of approximately 
20%26.
upon planning the therapeutic strategy for meta-
static MTC, one should keep in mind that metastatic 
MTC can have an indolent clinical course with a fa-
vorable long-term outcome; however, this is the case in 
only a portion of patients27. The others may have a rap-
idly progressing disease that requires immediate ther-
apy and close follow-ups. Asymptomatic patients with 
low-burden indolent MTC can be followed-up with-
out therapy. on the other hand, those with the symp-
tomatic, high-burden, rapidly progressing disease, or 
with lesions associated with a high risk of serious com-
plications (i.e. brain metastases, spinal cord compres-
sion, lesions compromising the airway, bone metasta-
ses with an imminent risk of pathologic fractures) re-
quire immediate therapy17. Multidisciplinary collabo-
ration (including surgeons specialized in thyroid 
surgery, endocrinologists, nuclear medicine specialists, 
oncologists, pain therapists, and palliative care person-
nel) of specialists with high patient volume enables the 
optimal care for these patients28.
in patients with progressive (within one year on 
imaging according to the ReCiST 1.1 criteria) and/or 
symptomatic metastatic disease, systemic therapy with 
targeted agents – vandetanib or cabozantinib, tyrosine 
kinase inhibitors – is indicated. if possible, patients 
should be included in clinical trials3.
Solitary or symptomatic metastases, especially in 
the liver or bone, should be considered for local treat-
ment (surgery, cryo-, thermo-, or chemoablation, /
chemo/embolization).
embolization or ablation can be beneficial in se-
lected cases in order to decrease tumor burden, pain, 
and even refractory diarrhea associated with liver me-
tastases29.
Symptomatic therapy is sometimes required, espe-
cially in cases of severe diarrhea. diarrhea, a possible 
paraneoplastic symptom, may appear in patients with 
advanced MTC due to high levels of calcitonin, vip, 
or increased intestinal motility. Antimotility agents, 
such as loperamide, may be used to ease the symptoms. 
in persistent diarrhea, somatostatin analogues can al-
leviate the symptoms. For patients with extensive liver 
metastases, various types of local liver-directed therapy 
may reduce the calcitonin levels and consequently 
symptoms of diarrhea. only rarely, paraneoplastic 
Cushing’s syndrome can occur (in 0.7% of cases) due 
to the secretion of ectopic hormones CRh or ACTh.
The management of advanced, metastatic, and pro-
gressive MTC remains challenging. patients with dis-
tant metastatic disease have a 10-year overall survival 
rate of <40%, compared with 75% in patients with re-
gional metastases and 96% of patients with localized 
disease30.
over the last decades, new insights into the signal-
ing pathways and numerous genetic aberrations in-
volved in the pathogenesis of cancer have led to the 
development and use of molecular targeted therapies31.
protein kinases, by catalyzing the phosphorylation 
of the tyrosine residues in proteins, activate various in-
tracellular signaling pathways, cell proliferation, differ-
entiation, migration, and anti-apoptosis. Consequent-
ly, uncontrolled tyrosine kinase receptor activation is 
one of the main mechanisms of development and pro-
gression of malignancies.
in normal parafollicular thyroid cells, signaling 
pathways such as ReT, RAS/MApK, pi3K, c-MeT, 
and mToR regulate the wide range of intracellular 
processes, such as cell proliferation, differentiation, mi-
gration, and apoptosis. various molecular-driven ab-
normalities in these signaling pathways are involved in 
thyroid carcinogenesis.
ReT is a type of tyrosine kinase receptor. inhibi-
tion of the phosphorylation of the ReT protein by 
tyrosine kinase inhibitor (TKi) can down-regulate its 
downstream targets in the signaling pathway, conse-
quently causing inhibition of tumor growth.
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Tyrosine kinase inhibitors (TKis) may provide 
therapeutic benefit by blocking tyrosine kinase-depen-
dent oncogenic pathways. TKis may inhibit one or 
several tyrosine kinase receptors; the latter are often 
called multikinase inhibitors, MKis.
TKis are small molecules that specifically target 
and inhibit the tyrosine kinases. Since ReT is a form 
of tyrosine kinase receptor, TKis can inhibit the phos-
phorylation of the ReT protein, consequently leading 
to downregulation of its downstream targets, with sub-
sequent inhibition of tumor growth. Although multi-
kinase inhibitors inhibit RET kinase activity to some 
extent, their antitumor effect is mainly achieved by 
their strong inhibition of the key angiogenic pathway 
components, especially vascular endothelial growth 
factor receptor (veGFR).
in the management of MTC, numerous MKis 
have been evaluated in clinical trials (axitinib, apatinib, 
cabozantinib, gefitinib, imatinib, lenvatinib, motesanib, 
pazopanib, sorafenib, sunitinib, vandetanib); however, 
results are variable32-36. The majority of clinical studies 
reached phase 2, resulting mostly in the stabilization of 
the disease, while partial response rates vary from 
0-50%. The most interesting results came from clinical 
studies with sunitinib and lenvatinib, with response 
rates of 50% and 36%, respectively26.
until very recently, only two TKis, namely vande-
tanib and cabozantinib, have been approved by the 
FdA and the eMA for the treatment of advanced, 
progressive (within one year on imaging according to 
the ReCiST 1.1 criteria), and/or symptomatic meta-
static or locally/locoregionally advanced inoperable 
MTC, based on the results of the two phase 3 ran-
domized multicenter clinical trials (ZeTA – vande-
tanib registrational trial and eXAM – cabozantinib 
registrational trial)37, 38. in comparison with placebo, 
the therapy with these TKis significantly prolonged 
progression-free survival (pFS), with better overall re-
sponse rates (oRR) in patients with metastatic MTC39, 
40. no overall survival (oS) benefit was observed, ex-
cept for the prolonged oS in the subgroup of patients 
on cabozantinib therapy with RETM918T-positive 
MTCs (44.3 versus 18.9 months with placebo, hR 
0.60)40. other than this subgroup of patients, both 
drugs displayed RET/RAS status-independent effica-
cy. These drugs inhibit multiple tyrosine kinases that 
are functionally related, resulting in the disruption of 
their associated pathways. The kinases inhibited by 
vandetanib are ReT, veGFR, and eGFR, and the ki-
nases inhibited by cabozantinib are ReT, veGFR, c-
KiT, and MeT. Because of the different inclusion cri-
teria, trial designs, and the different patient popula-
tions, the results from the vandetanib and cabozantinib 
trials are not at all comparable. Both drugs are consid-
ered equally effective both in the first- and the second-
line regimens, with no clear evidence supporting one 
over the other as the first-line therapeutic choice. The 
decision which drug to use as the first-line therapy 
may be based on the potential toxicity profile of the 
drugs, if no RETM918T-mutation exists. in patients 
with RET918T or RAS-mutant MTCs, as shown in a 
subgroup analysis, a significant advantage in pFS and 
oS was achieved with cabozantinib therapy.
however, TKi-therapy is associated with signifi-
cant adverse effects, such as diarrhea, fatigue, rash, 
nausea, hypertension, hand-foot syndrome, and oth-
ers41. That is probably due to wide-spread ReT inhibi-
tion in “off-target” sites. This toxicity can negatively 
impact patient quality of life, and sometimes dose re-
ductions or, more rarely, permanent treatment discon-
tinuation is necessary42. patients on cabozantinib ther-
apy have increased TSh levels in almost 60% of cases 
during treatment; therefore, close and continuous 
monitoring of TSh levels is required. The prolonga-
tion of QTc-interval on eCG is rare, but severe side 
effect reported in approximately 8% of patients in a 
vandetanib registrational study. veGF-pathway in-
hibition associated toxicity (hypertension, hemor-
rhage, gastrointestinal perforation, fistula formation) 
was more frequent in cabozantinib-treated patients 
than in the placebo group in the registrational study. 
Additionally, some ReT disease-causing variants are 
non-responsive to multikinase inhibitor therapy, i.e. 
nonspecific ReT inhibitor therapy. Some of those 
ReT-variants also corresponds negatively to some 
other kinases.
Currently, novel small molecules selectively target-
ing ReT (rather than MKis) are in the spotlight of the 
ongoing phase 2 clinical trials harboring RET activat-
ing mutations43.
in addition, some forms of RET disease-causing 
variants, such as V804L and V804M variants, affect the 
active enzymatic site of ReT and can render all of the 
known non-specific ReT-inhibitors ineffective. More-
over, the v804 residue of the ReT backbone also cor-
responds to the gate-keeper position of some other ki-
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nases, such as c-KiT, eGFR, pdGFR, and Abl. The 
ReT-suppressing activity is essential for the antitumor 
effects of these selective ReT-inhibitors in MTC ther-
apy, while their antiangiogenic activity is negligible.
The most promising highly selective ReT-inhibi-
tor is an ATp-competitive small molecule called selp-
ercatinib (LOXO-292)44. Several randomized clinical 
studies with selpercatinib are still ongoing. however, 
FdA granted accelerated approval of selpercatinib for 
the treatment of RET-altered thyroid cancer in May 
2020, based on the results of the liBReTTo-001 
clinical trial. The drug is registered for the treatment of 
adult and pediatric patients (³12 years of age) with ad-
vanced or metastatic RET-mutant MTC who require 
systemic therapy (as well as for the treatment of adult 
or pediatric patients with advanced or metastatic RET 
fusion-positive thyroid cancer who require systemic 
therapy and who are radioactive iodine (RAi)-refrac-
tory and for the treatment of metastatic RET fusion-
positive non-small cell lung cancer). The clinical trial, 
regarding the subgroup of patients with MTC, en-
rolled 55 patients with RET-altered MTC who had 
previously been treated with cabozantinib, vandetanib, 
or both, as well as 88 systemic therapy-naive patients. 
The response rates were 69% and 73% in the prior-
treatment and no-prior-treatment groups, respectively. 
in the majority of patients, the responses lasted 6 
months or longer. in addition, selpercatinib has various 
favorable pharmacokinetic properties. The most com-
mon adverse effects of selpercatinib were diarrhea, 
high blood pressure, and liver toxicity. Serious side ef-
fects, including abnormal heart rhythms and pneumo-
nia, occurred in a third of study patients. Although 
most side effects could be managed, 5% of patients 
stopped treatment permanently because of serious side 
effects.
The other new and very promising highly selective 
small molecule that targets oncogenic ReT alterations 
is pralsetinib (BLU-667)45. The first clinical results are 
encouraging, showing clinical benefit and a favorable 
safety profile in a small number of patients with MTC 
treated in a phase 1 clinical study. however, we should 
await more data on a larger number of patients in 
phase 2 and 3 prospective randomized clinical trials.
The role of immunotherapy in the treatment of pa-
tients with MTC is still under investigation46. MTC is 
not considered a very immunogenic tumor, which is a 
prerequisite for the efficacy of immunotherapy. Several 
checkpoint inhibitors, a type of immunotherapeutic 
agents, including pembrolizumab and nivolumab 
(pd-1 inhibitors), as well as ipilimumab (CTlA4-
inhibitor) are being evaluated in phase 2 clinical trials 
for the treatment of metastatic MTC47.
due to the potential expression of somatostatin re-
ceptors (SSTRs) in a subset of MTC tumors, owing to 
its neuroendocrine origin, somatostatin analogue ther-
apy or i-131-MiBG therapy in the previous decades 
and lately the peptide receptor radionuclide therapy 
(PRRT) have been used48-50. The prerequisite for this 
therapy is the positive diagnostic imaging for the clin-
ically relevant expression of SSTRs. however, phase 2 
data on y-90-doTAToC therapy in a small number 
of metastatic MTC patients showed modest clinical 
benefit with only 29% of responders51. There is also 
some scarce data of pRRT using lu-177-doT-
ATATe, also with modest results.
There have been some attempts of radioimmuno-
therapy with bi-specific monoclonal antibodies, i-
131-labeled bivalent hapten; however, no randomized 
clinical trials have been conducted. The latest ATA 
guidelines recommend radioisotope therapy only in 
the context of a clinical trial.
numerous clinical trials for the treatment of meta-
static MTC are ongoing. Some of the questions to be 
answered include further evaluation of the efficacy of 
TKis or MKis, especially in lower doses, or in combi-
nations, or different administration regimens in order 
to minimize toxicity while achieving clinical benefit. 
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Sažetak
MedulARni KARCinoM ŠTiTnJAČe – pReGled ZnAČAJKi i novoSTi  
u SuSTAvnoM liJeČenJu
N. Dabelić, T. Jukić i A. Fröbe
Medularni karcinomi štitnjače (MKŠ) rijetke su zloćudne bolesti podrijetla parafolikularnih (C-stanica) štitnjače i čine 
oko 2-4% svih zloćudnih tumora štitnjače. MKŠ može biti sporadičan ili nasljedan, potonji kao dio Men 2 sindroma. 
 nasljedne mutacije protoonkogena RET (od engl. REarranged during Transfection) pokretačke su mutacije kod nasljednih 
MKŠ, dok su somatske RET mutacije, ili, rjeđe, RAS mutacije, opisane u tumorskom tkivu kod sporadičnih MKŠ. Genetski 
probir na nasljedne mutacije protoonkogena RET identificira nosioce nasljednih genetskih mutacija. To omogućuje primar-
nu (sprječavanje razvoja bolesti provođenjem profilaktičke totalne tireoidektomije) ili barem sekundarnu prevenciju bolesti 
(rano otkrivanje MKŠ-a). Radikalna operacija s kompletnom resekcijom tumora još je uvijek ključna u postizanju izlječenja 
kod MKŠ. naime, unatoč nedavnim dostignućima, liječenje uznapredovalog, metastatskog i progresivnog MKŠ-a i dalje 
predstavlja izazov. Metastatski MKŠ može biti indolentnog kliničkog tijeka, stoga je potrebno procijeniti kojeg bolesnika 
liječiti i kada liječenje započeti. Multidisciplinarni timovi različitih specijalista uključenih u dijagnostiku i liječenje bolesnika 
s MKŠ-om u visoko specijaliziranim centrima s velikim brojem bolesnika omogućuju njihovo optimalno zbrinjavanje. Mul-
tikinazni inhibitori (MKi) vandetanib i kabozantinib, odobreni su za liječenje progresivnog ili simptomatskog metastatskog/
neresektabilnog MKŠ. premda je ovo liječenje pokazalo dobit u preživljenju bez progresije bolesti (pFS, od engl. Progression 
Free Survival) uz veću ukupnu stopu odgovora (oRR, od engl. Overall Response Rate) naspram placeba, MKi nisu polučili 
dobit u ukupnom preživljenju (oS, od engl. Overall Survival), osim kod podskupine bolesnika s RETM918T-mutacijama na 
terapiji kabozantinibom. Multikinazni inhibitori su neselektivni, stoga je moguća značajna toksičnost terapije. nedavno su 
razvijene nove generacije tirozin-kinaznih inhibitora (TKi). ovi visoko selektivni ReT-inhibitori specifično su dizajnirani 
za visoko učinkovito i selektivno ciljanje onkogenih ReT alteracija, što ih čini obećavajućim lijekovima u liječenju uznapre-
dovalog MKŠ. Selektivni ReT-inhibitor selperkatinib vrlo je nedavno registriran za liječenje RET-mutiranih karcinoma 
štitnjače. 
Ključne riječi: medularni karcinom štitnjače; RET-protoonkogen; molekularna ciljana terapija; liječenje; novosti
